Phathom Pharmaceuticals Inc (NASDAQ: PHAT) kicked off on Tuesday, up 1.54% from the previous trading day, before settling in for the closing price of $3.90. Over the past 52 weeks, PHAT has traded in a range of $3.81-$19.71.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 1600.29% over the past five years. While this was happening, its average annual earnings per share was recorded 24.67%. With a float of $38.70 million, this company’s outstanding shares have now reached $68.52 million.
Let’s look at the performance matrix of the company that is accounted for 427 employees. In terms of profitability, gross margin is 85.57%, operating margin of -502.18%, and the pretax margin is -605.09%.
Phathom Pharmaceuticals Inc (PHAT) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Phathom Pharmaceuticals Inc is 44.42%, while institutional ownership is 60.24%. The most recent insider transaction that took place on Apr 07 ’25, was worth 16,740. In this transaction CFO and CBO of this company sold 3,678 shares at a rate of $4.55, taking the stock ownership to the 89,868 shares. Before that another transaction happened on Mar 13 ’25, when Company’s Director bought 10,000 for $4.42, making the entire transaction worth $44,200. This insider now owns 85,500 shares in total.
Phathom Pharmaceuticals Inc (PHAT) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 24.67% per share during the next fiscal year.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Trading Performance Indicators
Take a look at Phathom Pharmaceuticals Inc’s (PHAT) current performance indicators. Last quarter, stock had a quick ratio of 4.16. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.35, a number that is poised to hit -1.10 in the next quarter and is forecasted to reach -1.80 in one year’s time.
Technical Analysis of Phathom Pharmaceuticals Inc (PHAT)
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) saw its 5-day average volume 1.08 million, a negative change from its year-to-date volume of 1.17 million. As of the previous 9 days, the stock’s Stochastic %D was 11.79%. Additionally, its Average True Range was 0.57.
During the past 100 days, Phathom Pharmaceuticals Inc’s (PHAT) raw stochastic average was set at 2.51%, which indicates a significant decrease from 6.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 124.34% in the past 14 days, which was higher than the 96.66% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.31, while its 200-day Moving Average is $10.44. Nevertheless, the first resistance level for the watch stands at $4.04 in the near term. At $4.11, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.20. If the price goes on to break the first support level at $3.88, it is likely to go to the next support level at $3.79. The third support level lies at $3.72 if the price breaches the second support level.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Key Stats
The company with the Market Capitalisation of 275.76 million has total of 69,637K Shares Outstanding. Its annual sales at the moment are 55,250 K in contrast with the sum of -334,330 K annual income. Company’s last quarter sales were recorded 29,660 K and last quarter income was -74,450 K.
